Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.

Immunotherapy

XING Technologies Pty Ltd, Brisbane, QLD 4073, Australia.

Published: October 2022

Breast and prostate cancers are generally considered immunologically 'cold' tumors due to multiple mechanisms rendering them unresponsive to immune checkpoint blockade therapies. With little success in garnering positive outcomes in modern immunotherapeutic clinical trials, it is prudent to re-examine the role of immunogenic neoantigens in these cold tumors. Gene fusions are driver mutations in hormone-driven cancers that can result in alternative mutation-specific neoantigens to promote immunotherapy sensitivity. This review focuses on 1) gene fusion formation mechanisms in neoantigen generation; 2) gene fusion neoantigens in cancer immunotherapeutic strategies and associated clinical trials; and 3) challenges and opportunities in computational and liquid biopsy technologies. This review is anticipated to initiate further research into gene fusion neoantigens of cold tumors for further experimental validation.

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2022-0081DOI Listing

Publication Analysis

Top Keywords

gene fusion
12
clinical trials
8
neoantigens cold
8
cold tumors
8
fusion neoantigens
8
neoantigens
5
harnessing gene
4
gene fusion-derived
4
fusion-derived neoantigens
4
neoantigens 'cold' breast
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!